Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Thomas Flaig to Goserelin

This is a "connection" page, showing publications Thomas Flaig has written about Goserelin.

 
Connection Strength
 
 
 
0.148
 
  1. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glod? LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6.
    View in: PubMed
    Score: 0.082
  2. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
    View in: PubMed
    Score: 0.041
  3. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)